Global Human Somatotropin Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Human Somatotropin Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Human Somatotropin report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Human Somatotropin market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Growth Hormone Deficiency (GHD) and Turner Syndrome are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Human Somatotropin industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Human Somatotropin key manufacturers include Novo Nordisk, Pfizer, Eli Lilly, Merck Serono, F. Hoffmann-La Roche, Ferring Pharmaceuticals, GeneScience Pharmaceuticals, Ipsen and LG Life Sciences, etc. Novo Nordisk, Pfizer, Eli Lilly are top 3 players and held % sales share in total in 2022.
Human Somatotropin can be divided into Powder and Solvent, etc. Powder is the mainstream product in the market, accounting for % sales share globally in 2022.
Human Somatotropin is widely used in various fields, such as Growth Hormone Deficiency (GHD), Turner Syndrome, Chronic Renal Insufficiency and Prader Willi Syndrome, etc. Growth Hormone Deficiency (GHD) provides greatest supports to the Human Somatotropin industry development. In 2022, global % sales of Human Somatotropin went into Growth Hormone Deficiency (GHD) filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Human Somatotropin market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report

Novo Nordisk
Pfizer
Eli Lilly
Merck Serono
F. Hoffmann-La Roche
Ferring Pharmaceuticals
GeneScience Pharmaceuticals
Ipsen
LG Life Sciences
Sandoz International
Anhui Anke Biotechnology
Segment by Type
Powder
Solvent
Growth Hormone Deficiency (GHD)
Turner Syndrome
Chronic Renal Insufficiency
Prader Willi Syndrome
Small for Gestational Age
SHOX Deficiency
Others
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Human Somatotropin market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Human Somatotropin, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Human Somatotropin industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Human Somatotropin in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Human Somatotropin introduction, etc. Human Somatotropin Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Human Somatotropin market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
North America, Europe and Asia Pacific are the key regions for Human Somatotropin industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Human Somatotropin key manufacturers include Novo Nordisk, Pfizer, Eli Lilly, Merck Serono, F. Hoffmann-La Roche, Ferring Pharmaceuticals, GeneScience Pharmaceuticals, Ipsen and LG Life Sciences, etc. Novo Nordisk, Pfizer, Eli Lilly are top 3 players and held % sales share in total in 2022.
Human Somatotropin can be divided into Powder and Solvent, etc. Powder is the mainstream product in the market, accounting for % sales share globally in 2022.
Human Somatotropin is widely used in various fields, such as Growth Hormone Deficiency (GHD), Turner Syndrome, Chronic Renal Insufficiency and Prader Willi Syndrome, etc. Growth Hormone Deficiency (GHD) provides greatest supports to the Human Somatotropin industry development. In 2022, global % sales of Human Somatotropin went into Growth Hormone Deficiency (GHD) filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Human Somatotropin market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report

By Company
Novo Nordisk
Pfizer
Eli Lilly
Merck Serono
F. Hoffmann-La Roche
Ferring Pharmaceuticals
GeneScience Pharmaceuticals
Ipsen
LG Life Sciences
Sandoz International
Anhui Anke Biotechnology
Segment by Type
Powder
Solvent
Segment by Application
Growth Hormone Deficiency (GHD)
Turner Syndrome
Chronic Renal Insufficiency
Prader Willi Syndrome
Small for Gestational Age
SHOX Deficiency
Others
Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Human Somatotropin market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Human Somatotropin, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Human Somatotropin industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Human Somatotropin in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Human Somatotropin introduction, etc. Human Somatotropin Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Human Somatotropin market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
